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Polymorphisms of angiotensin converting enzyme and plasmino-
gen activator inhibitor-1 genes in diabetes and macroangiopathy.
Background. An insertion or deletion (I/D) polymorphism in
the angiotensin converting enzyme (ACE) gene and a 4/5-guanine
tract polymorphism (4G/5G) in the promoter region of the
plasminogen activator inhibitor-1 (PAI-1) gene are associated
with the plasma activities of these substances and with coronary
heart disease. In smooth muscle cells and mesangial cells, the
angiotensin II synthesized by ACE increases mRNA expression
and the activity of PAI-1, which promotes antifibrinolysis and the
accumulation of extracellular matrix. Therefore, ACE and PAI-1
polymorphisms may have a synergistic effect on diabetic nephrop-
athy and macroangiopathy.
Methods. Using multivariate logistic regression analyses, we
investigated the independent or synergistic effects of the ACE I/D
and PAI-1 4G/5G polymorphisms on the development of diabetic
nephropathy and macroangiopathy in 208 patients with non-
insulin dependent diabetes mellitus (NIDDM) over a 15 year
period.
Results. Advanced diabetic nephropathy, defined as impaired
renal function and diabetic retinopathy, was present in 98 pa-
tients. Manifest macrovascular diseases, confirmed by both clini-
cal signs and physical and laboratory examinations, were present
in 56 patients. There was no significant difference in the genotype
distribution of ACE or PAI-1 polymorphisms between subjects
with advanced nephropathy and those with normal renal function.
There was no significant difference in the renal survival rate
between patients with differing ACE or PAI-1 genotypes. Subjects
with macroangiopathy had a higher frequency of the DD genotype
than those without macroangiopathy. Subjects with both DD and
4G4G genotypes had a higher incidence of macroangiopathy than
those with any other pair of genotypes. Multivariate logistic
regression analysis showed that there was no association between
ACE or PAI-1 polymorphisms and diabetic nephropathy. The
ACE DD genotype and its interaction with the PAI-1 4G4G
genotype and the presence of advanced diabetic nephropathy
were positively associated with macrovascular disease.
Conclusion. These results indicate that the ACE DD genotype
and its interaction with the PAI-1 4G4G genotype are indepen-
dent risk factors for macroangiopathy, but not for the progression
of diabetic nephropathy in NIDDM patients, and that the geno-
typing of PAI-1 and ACE polymorphisms, especially in patients
with advanced diabetic nephropathy, may be useful for predicting
and preventing macroangiopathy-related events.
Diabetic nephropathy is a major contributor to mortality
in patients with non-insulin dependent diabetes mellitus
(NIDDM), mainly because of its association with cardio-
vascular events [1, 2]. Hypertension and poor control of
hyperglycemia are risk factors for the development of
diabetic nephropathy [3, 4]. However, diabetic nephropathy
appears to be related to a genetic susceptibility in patients
with NIDDM because it affects only one third of subjects
with a history of diabetes for 20 years or more [5] and it has
demonstrated a familial predisposition [6].
Recent studies have shown that angiotensin converting
enzyme (ACE) inhibition not only improves clinical prog-
nosis of patients with myocardial infarction [7, 8], but also
slows the progressive decline of renal function in patients
with insulin-dependent diabetes mellitus (IDDM) [9]. An
insertion and deletion (I/D) polymorphism in the ACE
gene has been reported to be associated with the develop-
ment of diabetic nephropathy [10–12], as well as with
ischemic heart disease [13, 14]. The DD genotype is
associated with increased circulating and tissue ACE activ-
ity [15, 16] and is a risk factor for diabetic nephropathy [11,
12] and ischemic heart disease [13, 14]. The angiotensin II
generated by ACE has a vasoconstrictive effect, and pro-
motes proliferation of mesangial cells and smooth muscle
cells and the accumulation of extracellular matrix [17, 18].
In addition to these effects, angiotensin II induces the
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production of plasminogen activator inhibitor-1 (PAI-1) in
smooth muscle cells, endothelial cells, and mesangial cells
[19, 20]. PAI-1 is a key regulator of plasmin-mediated
proteolytic cascades, and plays an inhibitory role in both
fibrinolysis and extracellular matrix degradation [21]. In
animal studies of endothelial injury in the aorta [22] and
the kidney [23], ACE inhibition suppressed the increased
PAI-1 expression in the injured areas of intima and glo-
meruli, and diminished tissue lesions via the inhibition of
angiotensin II and PAI-1 production. Therefore, the reduc-
tion of PAI-1 activity by ACE inhibition may partially
account for the protective effects of ACE inhibitors on
organs.
Recent studies have shown that a 4/5-guanine (4G/5G)
tract polymorphism in the promoter region of the PAI-1
gene is related to the serum levels of PAI-1 and to the
occurrence of myocardial infarction [24, 25]. The 4G4G
genotype is associated with higher levels of transcriptional
activity of the PAI-1 gene and circulating PAI-1 activity
than the 5G5G genotype, and is more strongly related to
the occurrence of myocardial infarction than the 4G5G and
5G5G genotypes. PAI-1 may promote antifibrinolysis and
collagen accumulation in smooth muscle cells and mesan-
gial cells [21, 26], suggesting that the PAI-1 polymorphism
may be involved in the progression of nephropathy and in
macrovascular events in diabetic patients. The above-men-
tioned interaction between ACE activity and PAI-1 pro-
duction suggests that ACE and PAI-1 genetic polymorphisms
may have synergistic effects on diabetic nephropathy and
macroangiopathy.
We investigated the relationship between polymorphisms
in the ACE and PAI-1 genes and the development of
diabetic nephropathy and macroangiopathy in patients with
NIDDM. We compared the frequencies of genotypes and
alleles of the polymorphisms between patients with and
without decreased renal function and between patients with
and without macroangiopathy. We used multivariate logis-
tic regression analysis to examine the influence of various
factors, including the genotypes, on decreased renal func-
tion and macroangiopathy. We also examined the relation
between genetic polymorphisms and the time from the
onset of diabetes to the initiation of chronic hemodialysis.
METHODS
Subjects
During July 1996 and January 1997, we selected 208
Japanese patients (106 males and 102 females aged 41 to 79
years, mean 61.9 years) from the outpatient clinics of
Niigata University Hospital and Fukui Medical School
Hospital, and from dialysis centers in the Niigata and Fukui
prefectures, according to the following criteria: (1) all
subjects had been diagnosed with NIDDM according to the
criteria of the National Diabetes Data Group (NDDG); (2)
they had had no overt proteinuria at the known onset of
diabetes, as defined by a positive urine dipstick test; (3)
they had diabetes for over 15 years and had at least three
years of followed-up immediately prior to the study; (4)
each provided informed consent; (5) hemodialysis patients
lacking diabetic retinopathy (N 5 2) were excluded from
the study. Subjects thus selected were divided into groups
according to renal function as follows: 110 had stable renal
function defined as normal levels of serum creatinine (#1.2
mg/dl) and normoalbuminuria (N 5 101) to microalbumin-
uria (N 5 9) for at least three years immediately prior to
the study [Group DN(2)]; 98 patients, including 24 pa-
tients with overt proteinuria, impaired renal function but
not on dialysis, and simple or proliferative diabetic retinop-
athy, had decreased renal function [Group DN(1)]. Dia-
betic nephropathy had been diagnosed based on renal
biopsies in 12 of these patients not on dialysis. Group
DN(1) also included 74 patients with end-stage renal
failure requiring dialysis prior to the study and with overt
proteinuria and proliferative diabetic retinopathy before
the initiation of dialysis. Hemodialysis (HD) was per-
formed by expert nephrologists in patients with severe
uremic symptoms and/or a serum creatinine level above 8
mg/dl and a blood urea nitrogen level above 100 mg/dl.
None of the subjects had habitually taken antioxidant
vitamins or non-steroidal anti-inflammatory drugs before
the study [Group DN(2)] or before the initiation of HD
[Group DN(1)]. Smoking habit was defined on the basis of
current cigarette smoking for Group DN(2) and on habit-
ual smoking before the initiation of HD for Group DN(1).
Hypertension was defined as a systolic blood pressure .160
mm Hg or a diastolic pressure .90 mm Hg or the use of
antihypertensive drugs.
Venous blood samples (plasma and serum) were col-
lected after an overnight fast. The serum level of choles-
terol was measured by the standard enzymatic method.
Genotyping of PAI-1 and ACE was also performed using
blood samples obtained from 158 HD patients with nondi-
abetic renal disease and from 177 healthy controls without
renal disease or vascular disease (43.7 6 15.4 years; 95
males, 82 female).
Assessment of macrovascular disease
In order to investigate the effect of ACE and PAI-1
polymorphisms on macroangiopathy, we examined whether
or not each subject had apparent macroangiopathy accord-
ing to the following criteria.
Coronary heart disease. A previous myocardial infarction
was defined as heart attack that was diagnosed by a
physician based on chest pain, electrocardiogram (ECG)
changes, and enzyme determinations or the results of
coronary angiography. A 12-lead resting ECG was per-
formed in all patients. In patients with chest pain and
ischemic ECG abnormalities, a bicycle exercise test or
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dipyridamole thallium scintigraphy was performed. Pa-
tients with a normal resting ECG who had clinical symp-
toms underwent no further examinations.
Peripheral arteriopathy. The presence of peripheral arte-
riopathy was determined based on the patient history and a
physical examination. Symptoms of intermittent claudica-
tion were recorded by a physician on a standardized
questionnaire [27]. The presence of clinical signs of periph-
eral arteriopathy was determined by a physical examina-
tion, including palpation of pulses and auscultation of
bruits at the level of the femoral, popliteal, posterior tibial
and dorsal pedis arteries. In patients with clinical signs, the
vascular status of the lower extremities were assessed by
measurement of the ankle and arm systolic blood pressures
and peripheral artery angiography. An ankle/arm index ,
0.95 indicated the presence of peripheral arteriopathy.
Cerebral vascular disease. Cerebral vascular disease was
defined as a minor occlusive stroke (acute loss of cerebral
function with symptoms lasting for 24 hr or more) docu-
mented by computed tomography or a transient ischemic
attack (acute loss of cerebral function with symptoms
lasting for 24 hr or less).
A patient was considered to have macroangiopathy when
at least one of three vascular diseases (coronary heart
disease, peripheral arteriopathy, or cerebral vascular dis-
ease) was present. Manifest macroangiopathy was identi-
fied in 56 patients [Group MA(1)]. Coronary heart dis-
ease, peripheral arteriopathy and cerebral vascular disease
were identified in 16, 21, and 21 patients, respectively. One
patient had both coronary heart disease and cerebral
vascular disease, and one patient had both peripheral
arteriopathy and cerebral vascular disease. The remaining
152 NIDDM patients had no apparent macroangiopathy
[Group MA(2)].
Determination of the albumin excretion rate
Twenty-four hour urine samples were collected from all
patients in Group DN(2). Urinary albumin excretion rate
(AER) was measured by the latex agglutination nephelo-
metric immunoassay (LA System, Eiken, Tokyo, Japan)
and is expressed as the mean of two consecutive 24-hour
urine samples. The upper limits of normoalbuminuria and
microalbuminuria were set at 20 and 200 mg/min, respec-
tively. Overt proteinuria was defined as protein excretion of
0.5 g/day or macroalbuminuria (.200 mg/min).
Determination of PAI-1 4G/5G and ACE I/D genotypes
PAI-1 4G/5G genotype. Genomic DNA was extracted
from peripheral blood leukocytes using a commercial kit
(Collectagene; Takara, Ootsu, Shiga, Japan). A DNA frag-
ment covering the polymorphic site of the promoter region
was amplified by PCR using a pair of amplification primers
that flanked the 132-bp or 133-bp region, as shown in
Figure 1. The primers used were 59-TCCAACCTCAGC-
CAGACAAG-39 (PAI-1pr1) and 59-TGGTCTTTCCCT
CATCCCTG-39 (PAI-1pr2). The amplification reaction
mixture consisted of 1 mg of genomic DNA, 0.4 mM of each
primer, 0.125 mM of each dNTP, 2.5 mL of a 103 buffer
(100 mM of Tris-HCl pH 8.3, 500 mM of KCl, 15 mM of
MgCl2), and 1.25 U of Taq DNA polymerase (Takara) in a
final volume of 25 ml. The reaction mixture was subjected
to 35 cycles of 45 seconds at 94°C, 60 seconds at 65°C, and
25 seconds at 72°C. The final cycle was 10 minutes at 72°C.
The PCR product (8 ml) was mixed with 16 ml of 950
ml/liter formamide, 50 mg/liter bromophenol blue, 50
mg/liter xylene cyanol, and 20 mmol/liter EDTA 2Na. The
sample mixture was left in a boiling-water bath for five
Fig. 1. DNA sequence of the plasminogen
activator inhibitor-1 (PAI-1) promoter. A 200-
bp region of PAI-1 gene covering the 4G/5G
polymorphic site of the promoter is shown. The
forward primer (PAI-1 pr1) and the reverse
primer (PAI-1pr2) are underlined. The
numbers on the DNA sequence denote the
position of the nucleic acids from the start of
transcription. The arrow indicates an insertion
site of one guanine 675-bp upstream from the
start of transcription.
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minutes, cooled on ice for 10 minutes, and then electro-
phoresed through a 12% polyacrylamide non-denaturing
gel containing 0.53 TBE (45 mM of Tris-borate, 1 mM of
EDTA, pH 8.3) and 5% glycerol at a constant voltage of
200 V at 4°C until xylene cyanol migrated to the end of the
gel. PCR products from 4G4G and 5G5G homozygotes
were electrophoresed as standards together with samples of
the study subjects. After electrophoresis, single-stranded
conformers were visualized with a silver-staining kit (Bio-
Rad Laboratories, Richmond, CA, USA) according to the
manufacturer’s directions.
Sequence analysis of PAI-1 PCR products. The PCR
products of the promoter region of the PAI-1 gene were
purified by electrophoresis on a 2% agarose gel, electro-
eluted, cloned into the pGEM-T vector (Promega, Madi-
son, WI, USA) and sequenced. The DNA insert cloned into
pGEM-T vector served as the template for sequencing with
the Sequenase version 2.0 (Amersham International plc,
Buckinghamshire, UK). For direct sequencing, the electro-
eluted PCR products were desalted, lyophilized and re-
solved in 25 ml of distilled water. Sequencing reactions were
performed using at least 200 ng of the purified PCR
product, 20 ng of primer (either PAI-1pr1 or PAI-1pr2) and
a fluorescent-labeled Taq DyeDeoxyy terminator mix (Ap-
plied Biosystems, Foster City, CA, USA) according to the
manufacturer’s instructions. The DNA sequence was deter-
mined using the 373A Automated DNA Sequencer (Ap-
plied Biosystems). Both strands were sequenced for verifi-
cation.
ACE I/D genotype. Genotyping of the ACE I/D genotype
was performed by the method of Rigat et al [28] with a
slight modification. Briefly, polymerase chain reaction
(PCR) was performed using specific oligonucleotide prim-
ers. The PCR reaction mixture consisted of 1 mg of
genomic DNA, 0.2 mM of each primer, 50 mM of each dNTP,
2.5 ml of 103 buffer (100 mM of Tris-HCl, pH 8.3, 500 mM
of KCl, 15 mM of MgCl2), and 1.25 U of Taq DNA
polymerase (Takara) in a final volume of 25 ml. The
reaction mixture was subjected to 35 cycles of 45 seconds at
94°C, 60 seconds at 60°C and 60 seconds at 72°C. The final
cycle was 10 minutes at 72°C. The PCR product was
electrophoresed on 2% agarose gel. After electrophoresis,
the gel was stained with ethidium bromide and visualized by
UV transillumination.
To increase the specificity of DD genotyping, another
PCR using an insertion-specific primers was performed by
the method previously reported [29] with a slight modifi-
cation. In brief, PCR reaction mixture (25 ml) consisted of
1 mg of genomic DNA, each primer (0.2 mM), each dNTP
(50 mM), 2.5 ml of 103 buffer (100 mM Tris-HCl pH 8.3, 500
mM KCl, 15 mM MgCl2), and 1.25 U of Taq DNA polymer-
ase (Takara). The reaction mixture was subjected to 32
cycles of 45 seconds at 94°C, 60 seconds at 67°C and 60
seconds at 72°C. The final cycle was 10 minutes at 72°C.
Only the I allele produced a 335-bp DNA fragment. The
reaction yielded no products in the samples of DD geno-
type.
Statistical analysis
Continuous variables are expressed as the mean 6 SD.
Differences in continuous variables between Group DN(2)
and Group DN(1), between Group MA(2) and Group
MA(1), and among genotypic groups, were assessed by a
nonparametric test (Mann-Whitney U-test) and analysis of
variance (ANOVA). Chi-square analysis was used to com-
pare the distribution of genotypes and alleles of the ACE
and PAI-1 polymorphisms between Group DN(2) and
Group DN(1) and between Group MA(2) and Group
MA(1), and to assess between-group differences in non-
continuous variables. The interval from the known onset of
diabetes to the initiation of permanent HD was evaluated
based on Kaplan-Meier survival curves and the log-rank
test. We used the SAS (Statistical Analysis System) where
the LIFETEST procedure was employed [30]. Multivariate
logistic regression analysis using the SPSS computer soft-
ware was used to assess the independent contribution of
different variables to nephropathy or macroangiopathy in
diabetic patients. A level of P , 0.05 (two-tailed) was
considered statistically significant.
RESULTS
Genotyping of PAI-1 polymorphism
Polymerase chain reaction using the specific primers
PAI-1pr1 and PAI-1pr2 yielded a single band of approxi-
mately 130 bp (data not shown). Single-strand conforma-
tional polymorphism (SSCP) analysis of the PCR products
showed three distinct patterns of DNA separation: pattern
A (lanes 2, 8, and 11; Fig. 2), pattern B (lanes 1, 3 to 7, and
10) and pattern C (lanes 9 and 12). Sequence analysis
identified pattern A (lane 2 in Fig. 2) as a 4G4G homozy-
gote (Fig. 3A) and pattern C (lane 9 in Fig. 2) as a 5G5G
homozygote (Fig. 3B). Because pattern B was expected to
be a 4G5G heterozygote, the PCR products for lanes 1 and
3 to 7 were each cloned and sequenced. These sequence
analysis identified pattern B as a 4G5G heterozygote. In the
Group MA(1) and the Group DN(1), all samples of
pattern A (N 5 37) and pattern C (N 5 15) were submitted
to direct sequencing and shown to be a 4G4G homozygote
and a 5G5G homozygote, respectively. This SSCP analysis
showed no patterns other than these three separations in
the PCR products of all subjects.
Diabetic nephropathy and genetic polymorphisms in
PAI-1 and ACE
There were no significant differences in age, the sex
ratio, the incidence of smoking or the duration of diabetes
between Group DN(2) and Group DN(1) (Table 1). The
serum level of cholesterol was higher, and the incidence of
hypertension was lower in Group DN(2) than in Group
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DN(1). The incidences of proliferative retinopathy and
overt proteinuria were significantly higher in Group
DN(1) than in Group DN(2). Age of controls was signif-
icantly lower than those of Group DN(2) and Group
DN(1) (Table 1). There was no significant difference in the
distribution of PAI-1 4G/5G genotypes between the
NIDDM patients and healthy controls (4G4G/4G5G/
5G5G: 64/116/28 vs. 66/80/31). The allelic frequencies of
4G and 5G were similar in NIDDM patients and healthy
controls (4G/5G: 58.7%/41.3% vs. 59.9%/40.1%). There
was no significant difference in the distribution of ACE I/D
genotypes between the NIDDM patients and healthy con-
trols (II/ID/DD: 86/85/37 vs. 70/79/28) or in the allelic
frequencies between NIDDM patients and healthy controls
(I/D: 58.7%/41.3% vs. 61.9%/38.1%).
There was no significant difference in the genotype or
allele frequency of PAI-1 polymorphism among groups
(Table 2), and no significant difference in the genotype
distribution (II/ID/DD: 45/45/20 vs. 41/40/17) or allele
frequency (I/D: 61.4%/38.6% vs. 62.2%/37.8%) of ACE
Fig. 2. Single-strand conformational polymorphism (SSCP) analysis of polymerase chain reaction (PCR)-amplified DNA. (A) Samples containing
single-stranded PAI-1 DNA were separated by electrophoresis on a 10% polyacrylamide gel and stained with a silver reagent. Lanes 2, 8 and 11 are
4G4G homozygote. Lanes 1, 3 to 7, and 10 are 4G5G heterozygote. Lanes 9 and 12 are 5G5G homozygote. (B) Three distinct separation patterns (A,
B and C) by SSCP analysis are illustrated. Lanes 2, 8 and 11 show pattern A. Lanes 1, 3 to 7, and 10 show pattern B. Lanes 9 and 12 show pattern C.
Fig. 3. DNA sequences of the 4G/5G polymorphic region of the PAI-1 promoter. (A) Direct sequencing of the PCR product shown in lane 8 in Figure
1. The 4-guanine tract was verified in both the sense strand (top) and the antisense strand (bottom). (B) Direct sequencing of the PCR product shown
in lane 9 in Figure 1. The 5-guanine tract was verified in both the sense strand (top) and the antisense strand (bottom).
Kimura et al: Diabetic angiopathy and genetic polymorphisms 1663
polymorphism between Group DN(2) and Group DN(1).
Subjects with the ACE II genotype were significantly older
than subjects with the DD genotype, but no other clinical
characteristics were related to the genotype (Table 3). The
frequency of ACE inhibitor use before the initiation of HD
was similar in non-HD patients and HD patients (22.4% vs.
16.2%). Moreover, no significant difference in the fre-
quency of the drug use was observed among ACE geno-
types in non-HD patients (II vs. ID vs. DD: 18.2% vs.
25.0% vs. 26.1%) or in HD patients (II vs. ID vs. DD:
19.4% vs. 10.3% vs. 21.4%). As for the subgroup with a
history of ACE inhibitor use, the genotype distribution of
ACE polymorphism was similar in HD patients and
non-HD patients (DD/ID/II: 3/3/6 vs. 6/14/10). Concerning
the subgroup without a history of ACE inhibitor use, it was
also similar in the HD patients and non-HD patients
(DD/ID/II: 11/26/25 vs. 17/42/45).
To examine the impact of PAI-1 and ACE polymor-
phisms on the clinical course in terms of renal function, we
compared the time lag from the identifiable onset of
diabetes to the initiation of hemodialysis among PAI-1 and
ACE genotypes. There was no significant difference in the
renal survival rate for kidney as a functioning organ among
PAI-1 4G/5G genotypes (Fig. 4) or among ACE I/D
genotypes (Fig. 5).
When multivariate logistic regression analysis was per-
formed using age, the duration of diabetes, hypertension,
sex, cigarette smoking, the 5G allele, the I allele, and the
interaction between polymorphisms as variables, hyperten-
sion (P , 0.001) and the diabetes duration (P 5 0.0305)
showed a positive and independent association with dia-
betic nephropathy. Age was negatively associated with
diabetic nephropathy (P 5 0.0184). ACE and PAI-1 poly-
morphism or their interaction were not related to advanced
diabetic nephropathy (P 5 0.993, P 5 0.4478 and P 5
0.504, respectively). Diabetic retinopathy was excluded
from this model because all subjects in Group DN(1) had
simple or proliferative diabetic retinopathy according to
the criteria for inclusion in Group DN(1).
When the patients with microalbuminuria were omitted
from the study subjects, no significant difference between
Group DN(2) and Group DN(1) was seen in terms of the
genotype distribution of ACE polymorphism (DD/ID/II:
18/43/40 vs. 17/40/41) and PAI-1 polymorphism (4G4G/
4G5G/5G5G: 34/54/13 vs. 28/58/12). The multivariate logis-
tic analysis showed results similar to those from the subjects
including the microalbuminuric patients (data not shown).
Macroangiopathy and genetic polymorphisms in PAI-1
and ACE
Age and the incidences of hypertension and smoking
were similar in Group MA(2) and Group MA(1) (Table
4). There was no significant difference in the frequency of
ACE inhibitor use before and at the vascular events
between Group MA(2) and Group MA(1) (31% vs.
37.5%). The duration of diabetes was longer, the serum
level of cholesterol was lower, and the incidence of prolif-
erative retinopathy was higher in Group MA(1) than in
Group MA(2) (Table 4). Group MA(1) included higher
Table 1. Characteristics of Group DN(2) and Group DN(1) subjects and controls
Group DN(2)
(N 5 110)
Group DN(1)
(N 5 98)
Controls
(N 5 177)
Age years 63.3 6 9.2 61.4 6 11.3 43.7 6 15.4c
Gender male/female 51/59 55/43 95/82
Duration of diabetes years 20.0 6 4.6 21.2 6 5.3 —
Serum cholesterol mg/dl 201 6 36 171 6 55a 187 6 30c
Hypertension % 62 (55%) 83 (85%)b 0 (0%)d
Proliferative retinopathy % 25 (23%) 78 (89%)b —
Microalbuminuria % 9 (8%) 0 (0%)b —
Overt proteinuria % 0 (0%) 98 (100%)b 0 (0%)e
Patients on dialysis % 0 (0%) 74 (76%)b 0 (0%)e
Smoking % 45 (41%) 51 (52%) —
Group DN (2) consists of NIDDM patients with normal renal function. Group DN (1) consists of NIDDM patients with decreased renal function.
a P , 0.01 vs. Group DN(2) by Mann-Whitney U-test
b P , 0.01 vs. Group DN(2) by chi-square analysis
c P , 0.01 vs. Group DN(2) and Group DN(1) by Mann-Whitney U-test
d P , 0.01 vs. Group DN(2) and Group DN(1) by chi-square analysis
e P , 0.01 vs. Group DN(1) by chi-squared analysis.
Table 2. Genotype and allele frequencies of PAI-1
Genotype/alleles
Group
DN(2)
(N 5 110)
Group
DN(1)
(N 5 98)
Nondiabetic
HD patients
(N 5 158)
Controls
(N 5 177)
PAI-1 genotypes
4G/4G 36 28 59 66
4G/5G 58 58 73 80
5G/5G 16 12 26 31
Allele frequency
4G 0.591 0.582 0.604 0.599
5G 0.409 0.418 0.596 0.401
Group DN(2) consists of NIDDM patients with normal renal function.
Group DN(1) consists of NIDDM patients with decreased renal function.
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proportions of male patients and Group DN(1) patients
than Group MA(2) (Table 4).
There was no significant difference between Group
MA(1) and Group MA(2) in the genotype distribution
or in allele frequency of PAI-1 polymorphism (Table 4).
The DD genotype of the ACE gene was significantly
more frequent in Group MA(1) than that in Group
MA(2). The incidence of macroangiopathy was signifi-
cantly higher in subjects with both DD genotype and
4G4G genotype than in subjects with neither the DD
genotype or the 4G4G genotype (58.3% vs. 21.7%, P ,
0.02). The frequency of ACE inhibitor use was similar in
these two subgroups (25% vs. 35.2%, respectively). More-
over, no significant difference in the frequency of the ACE
inhibitor use was observed among ACE genotypes in
Group MA(2) (II vs. ID vs. DD: 30.0% vs. 31.7% vs.
31.8%) or in Group MA(1) (II vs. ID vs. DD: 43.8% vs.
36% vs. 33.3%).
We examined the independent influence of different
variables on manifest macroangiopathy using a model of
multiple stepwise logistic regression. Model 1 included age,
the duration of diabetes, hypertension, sex, cigarette smok-
ing, decreased renal function, proliferative diabetic reti-
nopathy, the absence of 5G allele and the absence of the I
allele. Multiple stepwise logistic regression analysis using
model 1 showed that decreased renal function, the duration
of diabetes, male sex, and the DD genotype were positively
and independently associated with macroangiopathy (Table
5). Although the analysis using model 1 showed that the
4G4G genotype was not a significant predictor for mac-
roangiopathy, the 4G4G genotype appeared to be linked to
macroangiopathy because patients with the genotype had
an independent odds ratio of 2.06 (95% coefficient interval,
0.99 to 4.27; P 5 0.0524) after adjustment for all the other
variables introduced in model 1. Subjects with both DD
genotype and 4G4G genotype had a higher prevalence of
macroangiopathy than those neither the DD genotype or
4G4G genotype (58.3% vs. 21.7%, P , 0.02). Considering
these findings, we further examined whether there is a
synergistic effect between ACE and PAI-1 polymorphisms
on macrovascular diseases. Model 2 included the inter-
action between the 4G4G and DD genotypes in addition to
all of the variables in model 1. Multiple stepwise logistic
regression analysis showed that decreased renal function,
Fig. 4. Relationship between the PAI-1 4G/5G genotypes and the renal
survival rate in patients with NIDDM. There were no significant differ-
ences in the renal survival rate among 4G4G genotype ( ), 4G5G
genotype (00) and 5G5G genotype ( ).
Fig. 5. Relationship between the ACE I/D genotypes and the renal
survival rate in patients with NIDDM. There were no significant differ-
ences in the renal survival rate among DD genotype ( ), ID genotype
(00) and II genotype ( ).
Table 3. Clinical characteristics in relation to PAI-1 4G/5G and ACE I/D genotypes
PAI-1 4G/5G genotypes ACE I/D genotypes
4G4G (N 5 64) 4G5G (N 5 116) 5G5G (N 5 28) II (N 5 86) ID (N 5 85) DD (N 5 37)
Age years 62.2 6 11.3 63.2 6 9.8 59.9 6 9.4 63.9 6 9.7 62.0 6 9.9 58.9 6 12.2a
Gender male/female 34/30 61/55 11/17 44/42 42/43 20/17
Duration of diabetes years 20.6 6 5.2 20.8 6 5.1 19.6 6 4.0 20.5 6 3.8 20.7 6 5.0 19.8 6 4.2
Serum cholesterol mg/dl 190 6 50 184 6 47 190 6 53 182 6 43 197 6 52 196 6 49
Hypertension % 45 (70%) 76 (66%) 24 (86%) 60 (70%) 62 (73%) 23 (62%)
Proliferative retinopathy % 32 (50%) 62 (53%) 16 (57%) 48 (56%) 47 (55%) 19 (51%)
Smoking % 31 (48%) 54 (47%) 11 (39%) 38 (44%) 43 (51%) 15 (41%)
Overt nephropathy % 28 (44%) 58 (50%) 12 (43%) 41 (48%) 40 (47%) 17 (46%)
ACE genotypes (II/DI/DD) 24/28/12 52/43/21 10/14/4 — — —
a P , 0.05 vs. II genotype by one-way ANOVA with Scheffe’s post-hoc comparison
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the duration of diabetes, the interaction between geno-
types, and male sex were positively and independently
associated with macroangiopathy (Table 5). The interac-
tion item displaced the DD genotype by the analysis using
the model 2. While an independent odds ratio of macroan-
giopathy on patients carrying DD genotypes was 2.79, the
odds ratio on patients carrying both 4G4G and DD geno-
types further increased to 9.83. The serum level of choles-
terol, a known risk factor for atherosclerosis, was excluded
from logistic analyses because most patients in Group
DN(1) experienced vascular events after the initiation of
HD and would have had a lower serum level of cholesterol
at the vascular attack than that before the initiation of HD,
that is, at the overt proteinuric stage when hyperlipidemia
induced by the protein loss is frequently observed.
DISCUSSION
We used PCR-SSCP analysis with silver staining to
detect the 4G/5G polymorphism in the promoter region of
the PAI-1 gene. We found that genotype and allele fre-
quencies in healthy Japanese subjects were similar to those
in healthy European subjects determined by an allele-
specific oligo melting method [31]. The frequencies of
genotypes and alleles in Japanese NIDDM patients were
also similar to the frequencies in European NIDDM pa-
tients determined by PCR with allele-specific primers [32].
These findings indicate that the technique used to detect
the PAI-1 4G/5G polymorphism in the present study is as
reliable as the previously described methods [24, 32].
Although all PCR products were not sequenced in the
present study, we think that the PCR-SSCP analysis was
unambiguous for distinguishing heterozygotes from ho-
mozygotes for the following reasons: (1) we identified 37
patients (pattern A) as a 4G4G homozygote, 15 (pattern C)
as a 5G5G homozygote and 6 (pattern B) as a 4G5G
heterozygote by both SSCP and sequence analyses. (2) The
SSCP analysis in the present study showed no patterns
other than these three patterns when the PCR products of
all subjects were analyzed.
PAI-1 is a major and rapid inhibitor of plasminogen
activators and is believed to promote antifibrinolysis and
the accumulation of extracellular matrix by inhibiting plas-
min activity [21]. The PAI-1 4G/5G polymorphism is asso-
ciated with plasma PAI-1 activity in NIDDM patients [32]
and healthy subjects [25]. The 4G4G genotype is associated
with the highest level of PAI-1 activity. Although we
hypothesized that the PAI-1 polymorphism would influence
the progression of diabetic nephropathy, the present find-
ings showed that the polymorphism was not related to
diabetic nephropathy. The present study is the first to
examine the association between the PAI-1 polymorphism
and diabetic nephropathy to our knowledge, and it was
retrospectively performed. Hence, prospective studies will
be required to clarify whether or not the PAI-1 polymor-
phism has a genetic influence on diabetic nephropathy.
There was no association between ACE genetic polymor-
phisms and the presence of advanced diabetic nephropathy
in NIDDM patients in the present study. The results of
several previous reports on the relation between the ACE
I/D polymorphism and the incidence of diabetic nephrop-
athy has been inconclusive [10–12, 33, 34]. Some studies
have shown that the ACE polymorphism is associated with
the incidence of diabetic nephropathy, and have suggested
that the DD genotype is a risk factor and the II genotype is
a protective factor [10–12]. However, other studies have
found no relationship between ACE polymorphism and the
development of diabetic nephropathy [33, 34]. This discrep-
ancy in study results may be due, in part, to differences in
the criteria used to define diabetic nephropathy [11]. Only
a small proportion of NIDDM subjects with microalbumin-
uria progress to overt nephropathy; the microalbuminuria
often results from conditions such as hypertension and
aging [11]. Thus, in the present study, the microalbuminuric
stage was classified as incipient nephropathy to distinguish
it from clinical or advanced nephropathy. The frequency of
the DD genotype may be underestimated in patients with
advanced diabetic nephropathy because the DD genotype
is a risk factor for macroangiopathy, especially for ischemic
heart disease [13, 14]. Because we identified both the DD
genotype and advanced diabetic nephropathy as indepen-
dent risk factors for macroangiopathy, the frequency of the
DD genotype in Group DN(1) patients may have been
undervalued in the present study. This may be one reason
for the lack of an association between ACE polymorphism
or PAI-1 polymorphism and diabetic nephropathy.
Macrovascular diseases are common in diabetic patients
[35]. The major clinical manifestations result from athero-
sclerosis of the coronary arteries and the cerebral arteries
and of the large arteries of the lower extremities. The
frequency of vascular diseases increases as the diabetic
nephropathy progresses [36, 37]. Peripheral vascular dis-
ease occurs in about 15% of diabetic patients who have had
Table 4. Characteristics of Group MA(2) and Group MA(1) subjects
Group MA(2)
(N 5 152)
Group MA(1)
(N 5 56)
Age years 62.2 6 10.1 62.4 6 11.4
Gender male/female 69/83 37/19a
Duration of diabetes years 19.7 6 4.2 22.7 6 5.5b
Serum cholesterol mg/dl 196 6 46 177 6 51b
Hypertension % 103 (68%) 42 (75%)
Proliferative retinopathy % 73 (48%) 41 (73%)a
Group DN(1) patients % 59 (39%) 39 (70%)a
ACE genotypes (II/DI/DD) 70/60/22 16/25/15a
PAI-1 4G/5G genotypes
(4G4G/4G5G/5G5G) 42/88/22 22/28/6
Smoking (%) 64 (42%) 32 (57%)
Group MA(2) consists of NIDDM patients with no apparent macroan-
giopathy. Group MA(1) consists of NIDDM patients with manifest
macroangiopathy.
a P , 0.05 vs Group MA(2) by chi-square analysis
b P , 0.05 vs Group MA(2) by Mann-Whitney U-test
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diabetes for 10 years or longer [38], and the incidence of
cerebral vascular disease is increased in diabetic patients
with renal insufficiency [37]. Thus, cerebral infarction,
peripheral artery diseases, and ischemic heart disease are
frequent atherosclerotic diseases in NIDDM patients, es-
pecially in those with diabetic nephropathy. We examined
the effect of ACE and PAI-1 polymorphisms on macroan-
giopathies, including these three types of vascular disease.
The ACE DD genotype and the interaction between the
ACE DD genotype and the PAI-1 4G4G genotype were
independently and positively associated with macroangi-
opathy in NIDDM patients. The DD genotype is reportedly
a risk factor for myocardial infarction [13, 14]. Kogawa et al
showed that the D allele was independently associated with
the intima-media thickness (IMT) of the carotid artery in
NIDDM patients [39]. Because the DD genotype is related
to an increased local tissue level of ACE [15, 40] and the
increased circulating level of ACE [15], the NIDDM pa-
tients with the DD genotype may have elevated ACE
activities in plasma and vessel walls and may be vulnerable
to the atherosclerosis due to the increased local production
of angiotensin II in the vessel walls. In the present study,
decreased renal function, but not hypertension, was iden-
tified as a major risk factor for macroangiopathy, possibly
because about half of the study subjects had a decline in
renal function. Notably, high blood pressure does not seem
to increase the relative risk for cardiovascular-related mor-
tality in the patients on hemodialysis [41]. The mechanisms
whereby decreased renal function promotes the develop-
ment of macroangiopathy may be explained by the finding
that circulating ACE levels are further elevated with worse
nephropathy and the DD genotype [42]. The other mech-
anisms may be related to newly identified risk factors such
as hyperhomocysteinemia and elevated lipoprotein(a),
which are frequently observed in chronic renal failure and
dialysis patients [41].
It is generally accepted that the angiotensin II locally
synthesized by ACE promotes the proliferation of mesan-
gial cells, smooth muscle cells and the production of
extracellular matrix, and exerts a vasoconstrictive effect
[43]. Angiotensin II has also been shown to induce the
production of PAI-1 in smooth muscle cells, endothelial
cells and mesangial cells [19–20]. PAI-1 is a key regulator
of plasmin-mediated proteolytic cascades; its overproduc-
tion leads to antifibrinolysis and the accumulation of extra-
cellular matrix accumulation [21, 26]. Furthermore, in
animal studies of endothelial injury in the aorta [22] and
the kidney [23], ACE inhibition reduced the increased
PAI-1 expression in the injured tissue and diminished tissue
lesions. Considering these findings and the genetic effects
of ACE and PAI-1 polymorphisms on plasma activities of
these active substances, it seems reasonable to assume that
ACE and PAI-1 polymorphisms have synergistic effects on
diabetic nephropathy and macroangiopathy. In the present
study, multivariate logistic regression analyses showed that
the interaction between the ACE DD genotype and the
PAI-1 4G4G genotype was independently and positively
associated with macroangiopathy, but not with diabetic
nephropathy. This is the first report, to our knowledge, to
show that ACE and PAI-1 polymorphisms have synergistic
effects on macroangiopathy. However, this study is prelim-
inary. It did not include patients with subclinical macroan-
giopathy and only identified the angiopathy status of pa-
tients at one time point. Therefore, a prospective study of
a larger population of diabetic patients is required to
further elucidate the independent or synergistic effects of
ACE and PAI-1 polymorphisms on the development of
macroangiopathy and advanced diabetic nephropathy.
In summary, the ACE I/D polymorphism is significantly
associated with manifest macroangiopathy in NIDDM pa-
tients. The ACE I/D and PAI-1 4G/5G polymorphisms do
not appear to be related to the incidence of advanced
diabetic nephropathy. The interaction between the ACE
DD genotype and the PAI-1 4G4G genotype, and the DD
genotype alone are risk factors for macroangiopathy inde-
pendently of the duration of diabetes and the presence of a
Table 5. Multiple logistic regression analysis of the influence of selected variables on macroangiopathy in NIDDM patients
Variable Regression coefficient SE Odds ratio (95% CIa) P value
Model 1b
Decreased renal function 1.2539 0.3556 3.50 (1.75–7.03) 0.0004
Duration of diabetes 0.1008 0.0305 1.11 (1.04–1.17) 0.0010
Sex 0.8934 0.3550 2.44 (1.22–4.90) 0.0119
ACE DD genotype 1.0252 0.4351 2.79 (1.19–6.54) 0.0185
Model 2c
Decreased renal function 1.3601 0.3703 3.90 (1.89–8.05) 0.0002
Duration of diabetes 0.1082 0.0308 1.11 (1.05–1.18) 0.0004
Interaction between ACE DD genotype
and PAI-1 4G4G genotype
2.2850 0.7291 9.83 (2.35–41.02) 0.0017
Sex 0.8609 0.3681 2.37 (1.18–4.73) 0.0162
a CI, confidence interval
b Variables introduced into Model 1: age (year), the duration of diabetes (year), hypertension (absent 5 0, present 5 1), sex (female 5 0, male 5
1), cigarette smoking (absent 5 0, present 5 1), decreased renal function (absent 5 0, present 5 1), proliferative diabetic retinopathy (absent 5 0,
present 5 1), 5G allele (absent 5 1, present 5 0), and I allele (absent 5 1, present 5 0).
c Variables introduced into Model 2: all variables introduced into Model 1 and the interaction between PAI-1 4G4G genotype and ACE DD genotype.
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decreased renal function. These preliminary findings sug-
gest that the investigation of PAI-1 and ACE polymor-
phisms in patients with advanced diabetic nephropathy may
be useful for predicting and preventing macroangiopathy-
related events.
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APPENDIX
Abbreviations used in this article are: ACE, angiotensin converting
enzyme; AER, albumin excretion rate; ECG, electrocardiogram; 4G/5G,
4/5-guanine tract polymorphism; HD, hemodialysis; I/D, insertion dele-
tion; IDDM, insulin-dependent diabetes mellitus; NIDDM, non-insulin
dependent diabetes; PAI-1, plasminogen activator inhibitor-1; PCR, poly-
merase chain reaction; SSCP, single-strand conformational polymor-
phism.
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